Theriva Biologics (TOVX) Income from Non-Controlling Interests (2013 - 2021)
Theriva Biologics (TOVX) posted quarterly Income from Non-Controlling Interests of $1000.0 for Q1 2021, up 103.85% year-over-year from $490.57 in Q1 2020, and up 104.35% quarter-over-quarter from -$23000.0 in Q4 2020.
Theriva Biologics (TOVX) Income from Non-Controlling Interests (2013 - 2021) Analysis & Trends
Theriva Biologics (TOVX) has reported Income from Non-Controlling Interests for 8 consecutive years, with $1000.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Income from Non-Controlling Interests rose 103.85% year-over-year to $1000.0; the TTM figure through Dec 2021 stood at $1000.0 (up 101.37% YoY), while the FY2021 annual figure was -$1000.0, up 98.63% from the prior year.
- Income from Non-Controlling Interests rose to $1000.0 in Q1 2021 per TOVX's latest filing, from -$23000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1000.0 in Q1 2021 and bottomed at -$212000.0 in Q1 2017.
- Historically, Income from Non-Controlling Interests has averaged -$30588.2 across 5 years, with a median of -$16000.0 in 2018.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests tumbled 475.0% — and 2021, when it soared 103.85%.
- Theriva Biologics' Income from Non-Controlling Interests stood at -$38000.0 in 2017, then jumped by 50.0% to -$19000.0 in 2018, then surged by 78.95% to -$4000.0 in 2019, then sank by 475.0% to -$23000.0 in 2020, then jumped by 104.35% to $1000.0 in 2021.
- Business Quant data shows TOVX's Income from Non-Controlling Interests at $1000.0 in Q1 2021, -$23000.0 in Q4 2020, and -$8000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | -23,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | -16,000.00 |
| Mar 31, 2020 | -26,000.00 |
| Dec 31, 2019 | -4,000.00 |
| Sep 30, 2019 | -30,000.00 |
| Jun 30, 2019 | -27,000.00 |
| Mar 31, 2019 | -16,000.00 |
| Dec 31, 2018 | -19,000.00 |
| Sep 30, 2018 | -9,000.00 |
| Jun 30, 2018 | -16,000.00 |
| Mar 31, 2018 | -9,000.00 |
| Dec 31, 2017 | -38,000.00 |
| Sep 30, 2017 | -8,000.00 |
| Jun 30, 2017 | -60,000.00 |
| Mar 31, 2017 | -212,000.00 |
| Dec 31, 2016 | -97,000.00 |
| Sep 30, 2016 | -136,000.00 |
| Jun 30, 2016 | -82,000.00 |